Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma (BBIO) is a biopharmaceutical innovator developing genetic disease therapies through its unique portfolio-based approach. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and stakeholders gain centralized access to critical updates including clinical milestones, regulatory filings, financial disclosures, and research partnerships. Our curated feed ensures timely tracking of therapeutic advancements across BridgeBio's diversified pipeline.
Key focus areas include progress in Mendelian disorder treatments, oncology targets, and gene therapy innovations. All content undergoes strict verification to maintain compliance with financial disclosure standards and medical accuracy guidelines.
Bookmark this page for efficient monitoring of BBIO's scientific advancements and corporate developments. Combine this resource with SEC filings and earnings transcripts for comprehensive investment analysis.
LianBio and BridgeBio Pharma announced the treatment of the first patient in a Phase 2a clinical trial of infigratinib for gastric cancer with FGFR2 gene amplification in China. This study is critical due to China's high gastric cancer prevalence. Infigratinib, an FGFR inhibitor, is already approved in the U.S. for cholangiocarcinoma and is being evaluated for other cancers. The trial's primary endpoint is objective response rate, with significant implications for treatment options in Asia.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the addition of three independent directors to its board: Fred Hassan, a veteran of the pharmaceutical industry; Andrea Ellis, CFO of Lime; and Douglas Dachille, former CIO of AIG. These appointments aim to enhance BridgeBio's strategic direction and expand its commercial infrastructure as it advances therapies for genetic diseases. CEO Neil Kumar expressed confidence that their diverse expertise will strengthen the company's mission. BridgeBio, founded in 2015, is focused on innovative therapies for patients with genetic conditions.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported second-quarter financial results for the period ending June 30, 2021, with total revenues of $54.0 million. The company achieved its second FDA approval for TRUSELTIQ™ (infigratinib) for cholangiocarcinoma, a significant milestone. Operating costs rose to $148.0 million due to increased personnel and stock-based compensation, leading to a net loss of $102.1 million. Cash and cash equivalents totaled $898.4 million, highlighting a strong liquidity position despite rising expenses.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the granting of 21,414 restricted stock units to 17 new employees on August 3, 2021. This issuance is part of the company's 2019 Inducement Equity Plan, ensuring compliance with Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing innovative treatments for genetic diseases and cancers. The company has over 30 programs in its pipeline, aiming to expedite the delivery of its first approved therapy.
BridgeBio Pharma has announced a non-exclusive collaboration with Bristol Myers Squibb to evaluate BBP-398, a promising SHP2 inhibitor, in combination with OPDIVO® for treating advanced solid tumors with KRAS mutations. The collaboration includes a Phase 1/2 trial assessing the safety and efficacy of BBP-398 alongside OPDIVO as doublet therapy and with a KRASG12C inhibitor as triplet therapy in non-small cell lung cancer. Both companies will co-fund the clinical development activities. BRIDGE Bio aims to provide new treatment options for patients with difficult-to-treat cancers.
BridgeBio Pharma (Nasdaq: BBIO) announced on July 1, 2021, that its compensation committee granted 20 new employees restricted stock units totaling 26,761 shares. This was done as an inducement for new hires, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards were made under BridgeBio's 2019 Inducement Equity Plan, which aims to attract talent in the biopharmaceutical sector to develop treatments for genetic diseases and cancers. The company has over 30 ongoing development programs focused on advancing its first approved therapy.
BridgeBio Pharma (Nasdaq: BBIO) announced collaborations with three academic institutions: MUSC Foundation for Research Development, Stanford University, and the University of Pittsburgh. These partnerships aim to translate innovative research into therapies for genetic diseases and cancers. BridgeBio's CEO, Neil Kumar, emphasized the significance of these collaborations in accelerating the development of life-changing medicines. The company has previously partnered with 23 institutions, showcasing its commitment to advancing patient treatment options.
On June 1, 2021, BridgeBio Pharma (Nasdaq: BBIO) granted restricted stock units totaling 47,963 shares to 21 new employees under the 2019 Inducement Equity Plan. This action is compliant with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new hires. BridgeBio is dedicated to developing medicines for genetic diseases and cancers, with over 30 programs in its pipeline. Founded in 2015, the company focuses on rapid advancements in genetic medicine to benefit patients.
BridgeBio Pharma (Nasdaq: BBIO) announced that the FDA granted Fast Track designation to encaleret for treating autosomal dominant hypocalcemia (ADH1). This rare genetic condition affects approximately 12,000 people in the U.S., causing severe calcium regulation issues. Current treatments are insufficient. Promising early results from a Phase 2b study show 100% normalization of blood and urine calcium in participants. This designation may expedite development and approval of encaleret, potentially the first therapy specifically for ADH1.
BridgeBio Pharma and Helsinn announced the FDA's approval of TRUSELTIQ (infigratinib) for previously-treated patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion. This marked BridgeBio's first oncology product approved by the FDA and the second overall this year. In clinical trials, TRUSELTIQ demonstrated a objective response rate of 23% and a median duration of response of 5 months. The companies will co-commercialize TRUSELTIQ in the U.S., sharing profits and losses equally.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
